Financials data is unavailable for this security.
View more
Year on year Panacea Life Sciences Holdings Inc grew revenues 46.59% from 1.63m to 2.38m while net income improved from a loss of 9.14m to a smaller loss of 8.02m.
| Gross margin | -139.49% |
|---|---|
| Net profit margin | -277.51% |
| Operating margin | -192.25% |
| Return on assets | -42.65% |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, Panacea Life Sciences Holdings Inc increased its cash reserves by 1,352.09%, or 93.97k. Cash Flow from Financing totalled 1.68m or 70.60% of revenues. In addition the company used 1.52m for operations while cash used for investing totalled 65.32k.
| Cash flow per share | -0.3558 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.5255 |
|---|---|
| Tangible book value per share | -0.6901 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.2277 |
|---|---|
| Quick ratio | 0.0285 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | 4.79 |
More ▼
